1. A method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonists to the mammal.

2. The method of claim 1, wherein the method is used to treat a tumor growth or angiogenesis in the mammal.

3. The method of claim 1 or 2, wherein the RTK is Epidermal Growth Factor Receptor (EGFR).

4. The method of claim 3, wherein the extracellular RTK antagonist is cetuximab, ABX-EGF, EMD 72000, h-R3, or Y10.

5. The method of claim 3, wherein the intracellular RTK antagonist is ZD1939 or OSI-774.

6. The method of claim 1 or 2, wherein the RTK is HER2 receptor.

7. The method of claim 6, wherein the extracellular RTK antagonist is trastuzumab.

8. The method of claim 1 or 2, wherein the RTK is Vascular Endothelial Growth Factor Receptor (VEGFR).

9. The method of claim 8, wherein the extracellular RTK antagonist is bevacizumab.

10. The method of claim 1 or 2, wherein the intracellular RTK antagonist inhibits ras protein or a ras-raf modulator.

11. The method of any one of claims 1-10, wherein the method further comprises administrating an antineoplastic agent.

12. A pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist.

13. The pharmaceutical composition of claim 12, wherein the RTK is Epidermal Growth Factor Receptor (EGFR).

14. The pharmaceutical composition of claim 13, wherein the extracellular RTK antagonist is cetuximab, ABX-EGF, EMD 72000, h-R3, or Y10.

15. The pharmaceutical composition of claim 13 or 14, wherein the intracellular RTK antagonist is ZD1939 or OSI-774.

16. The pharmaceutical composition of any claim 12, wherein the RTK is HER2 receptor.

17. The pharmaceutical composition of claim 16, wherein the extracellular RTK antagonist is trastuzumab.

18. The pharmaceutical composition of claim 12, wherein the RTK is Vascular Endothelial Growth Factor Receptor (VEGFR).

19. The pharmaceutical composition of claim 18, wherein the extracellular RTK antagonist is bevacizumab.

20. The pharmaceutical composition of claim 12, wherein the intracellular RTK antagonist inhibits ras protein or a ras-raf modulator.

21. The pharmaceutical composition of any one of claims 12-20, wherein the pharmaceutical composition further comprises an antineoplastic agent.